Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VYD2311 for the Prevention of COVID-19 in Adults and Adolescents
NCT07298434Phase 3Active, not recruiting
- Sponsor
- Invivyd
- Start
- Jan 2026
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of VYD2311 in coronavirus disease 2019 (COVID-19), sponsored by Invivyd. Started Jan 2026; status: active, not recruiting.
02
Drugs
VYD2311
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07298434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07298434.